Oxazaphosphorine Cytostatics: Structure—Activity Relationships, Selectivity and Metabolism, Regional Detoxification

  • Norbert Brock
Chapter
Part of the Developments in Pharmacology book series (DIPH, volume 3)

Abstract

Progress in the field of chemotherapy of cancer depends decisively on whether we succeed in developing compounds with a higher selectivity of the antitumoral action and thus with a greater therapeutic range, i.e., less dangerous in clinical use. This has been the guiding principle in the work of the Asta research teams for over 30 years.

Keywords

Cytotoxic Activity Nitrogen Mustard Transport Form High Chemical Reactivity Cytotoxic Specificity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brock, N. Chem.Exp.Technol. 3, 441–448 (1977)Google Scholar
  2. 2.
    Druckrey, H, Raabe, S. Klin.Wschr. 30, 882–884 (1952)PubMedCrossRefGoogle Scholar
  3. 3.
    Arnold, H, Bourseaux, F, Brock, N. Nature 181, 931 (1958)PubMedCrossRefGoogle Scholar
  4. 4.
    Arnold, H, Bourseaux, F, Crock, N. Arzneim.-Forsch. (Drug Res.) 11, 143 (1961)Google Scholar
  5. 5.
    Brock, N. Experimental Basis of Cancer Chemotherapy. In: K. Hellmann and T.A. Connors (Eds), Chemotherapy Vol. 7, 1976, Plenung Publishing Corp., New York, p. 19Google Scholar
  6. 6.
    Brock, N. Pharmakologische Grundlagen der Krebs-Chemotherapie. In: A. Georgii, Verhandlungen der Deutschen Krebsgesellschaft,Band 1, 1978, Gustav Fischer Verlag, Stuttgart — New York, p. 15Google Scholar
  7. 7.
    Brock, N, Potei, J. Arzneim.-Forsch. (Drug Res.) 24, 1149 (1974)Google Scholar
  8. 8.
    Brock, N. Cancer Treat.Rep. 60, 301–307 (1976)PubMedGoogle Scholar
  9. 9.
    Brock, N, Hohorst, HJ. Z. Krebsforsch. 88, 185–215 (1977)Google Scholar
  10. 10.
    Peter, G, Wagner, T, Hohorst, HJ. Cancer Treat.Reports 60, 429–435 (1976)Google Scholar
  11. 11.
    Hohorst, HJ, Bielicki, L, Voelcker, G. The Mode of Action of Cyclophosphamide. 9th int. Symposium on the Biological Characterization of Human Tumours, 1981, Bologna.Google Scholar
  12. 12.
    Brock, N, Niemeyer, U, Pohl, J, Scheffler, G. Stabilised primary metabolites of oxazaphosphorine cytostatics with high cytotoxic specificity and cancerotoxic selectivity needing no enzymatic activation. Third NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1981, BrusselsGoogle Scholar
  13. 13.
    Brock, N, Pohl, J, Stekar, J. Europ.J.Cancer 17, 595–607 (1981)CrossRefGoogle Scholar
  14. 14.
    Brock, N, Pohl, J, Stekar, J. Europ.J.Cancer Clin. Onco1. 17, 1155–1168 (1981)CrossRefGoogle Scholar
  15. 15.
    Brock, N, Pohl, J, Stekar, J, Scheef, W. Europ.J.Cancer Clin.Oncol. 1982 in printGoogle Scholar
  16. 16.
    Ormstad, K, Orrenius, S, LSstbom, T, Uenara, N, Pohl, J, Brock, N. 1982 in printGoogle Scholar
  17. 17.
    Brock, N, Stekar, J, Pohl, J, Niemeyer, U, Scheffler, G. Arzneirn.Forsch. (Drug Res.) 29, 659–661 (1979)Google Scholar
  18. 18.
    Pohl, J, Brock, N, Stekar, J. Toxicology, Pharmacology and Interactions of Sodium 2-mercaptoethane sulfonate (Mesna). 12th int. Chemotherapy Congress, 1981, FlorenceGoogle Scholar
  19. 19.
    Habs, M, Schmdhl, D, Brock, N. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-rnercaptoethane sulfonate (mesna) and disodium 2,2’-dithio-bis-ethane sulfonate (dimesna). 13th int. Cancer Congress, 1982, SeattleGoogle Scholar
  20. 20.
    Kaufmann, B, Wegmann, W. Schweiz.med.Wschr. 111 540–545 (1981)PubMedGoogle Scholar
  21. 21.
    Hill, D.L. A review of cyclophosphamide. 1975. Charles C. Thomas Publ., Springfield, Ill.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague, Boston, London 1983

Authors and Affiliations

  • Norbert Brock
    • 1
  1. 1.Asta-Werke AG Degussa Pharma GruppeAbt. TumorforschungBielefeld 14Germany

Personalised recommendations